Loading
Cabozantinib, a kinase inhibitor blocking RET, MET and VEGF receptors, delayed progression by more than seven months compared with placebo in progressive medullary thyroid cancer, at the cost of considerable toxicity.
Phase 3 placebo-controlled trial of 330 patients with progressive metastatic medullary thyroid cancer randomised 2:1 to cabozantinib 140 mg daily or placebo.
Median progression-free survival was 11.2 versus 4.0 months (hazard ratio 0.28) and response 28 versus 0 percent, with benefit regardless of RET status; diarrhoea, hand-foot syndrome, weight loss and fistula were notable toxicities.
Cabozantinib is an option for progressive medullary thyroid cancer, now mainly for RET-negative disease or after selpercatinib.
Shares Rossella Elisei, Medullary thyroid cancer.
Shares Medullary thyroid cancer, Journal of Clinical Oncology.
Shares Medullary thyroid cancer, Cabozantinib.
Shares Medullary thyroid cancer, Cabozantinib.
Shares EXAM, Cabozantinib.
Shares Medullary thyroid cancer, Cabozantinib.